Top FDA Developments Of 2015 And Predictions For 2016

Law360, New York (January 11, 2016, 12:12 PM EST) -- 2015 ushered in several important events and key regulatory developments that significantly impacted the pharmaceutical and medical device industry. Some developments were contentious, and are likely harbingers of things to come in 2016. Below, we present our picks for the top regulatory developments of the past year, and some predictions for 2016.

A Change at the FDA's Helm

U.S. Food and Drug Administration Commissioner Margaret Hamburg retired at the end of March 2015.[1] Dr. Hamburg's influence on the FDA resulted in many positive developments, including: improved agency morale, increased numbers of drug approvals, record numbers of orphan drug approvals, decreased drug...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!